ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCAB TO Reconsider Decision Not To Fund Diet Fit Trial

October 20, 1989

Letter to the Editor

March 21, 2003

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

December 12, 2003

Double Trouble For NIH: Democrats Offer Small Increases, Bush May Veto The Bill.

July 6, 2007

Science Policy: Stem Cell Research Guidelines Formalize NIH Funding Polices

December 3, 1999

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

January 25, 2002